Last updated: February 20, 2026
What is the scope of patent CA2823218?
Patent CA2823218 is titled "COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA," with a filing date of March 24, 2014, and a grant date of May 28, 2019. It covers a novel class of compounds and their specific use in the treatment of leukemia, particularly acute myeloid leukemia (AML). The patent claims proprietary chemical structures, methods for synthesis, and their application in pharmaceutical compositions.
Key features:
- Chemical scope: The patent claims include pyrimidine-based compounds with specified substituents designed to inhibit specific kinase targets implicated in leukemia.
- Therapeutic methods: It covers methods of use, specifically administering these compounds to treat AML.
- Synthesis claims: Methods for preparing the compounds are claimed, emphasizing certain chemical processes.
- Pharmaceutical compositions: Formulations incorporating these compounds are protected.
The scope is focused but comprehensive, covering compounds, uses, and synthesis methods related to treatment of leukemia with kinase inhibition.
How broad are the claims?
| Claim Type |
Details |
Number of Claims |
| Compound claims |
20 claims, covering core structures with various substituents |
1-20 |
| Method of use claims |
2 claims covering treatment of AML with claimed compounds |
21-22 |
| Process/synthesis claims |
3 claims on methods for preparing compounds |
23-25 |
| Composition claims |
2 claims covering pharmaceutical formulations |
26-27 |
- Claim breadth: The core compound claims are moderately broad, covering main structural motifs with variations in substituents that modulate kinase activity.
- Use claims: Limited to AML, not generally extending to other leukemia types or cancers.
- Synthesis and formulation: Specific, with some claims directed to known chemical processes.
Claims are structured to defend the core chemical classes while enabling some flexibility for derivatives.
Patent landscape for leukemia kinase inhibitors
Key players and recent filings
| Patent/Patent Family |
Assignee |
Filing Year |
Focus Area |
| CA2823218 |
Novartis Pharmaceuticals |
2014 |
AML treatment via kinase inhibitors |
| US20190283409 |
BeiGene |
2019 |
Kinase inhibitors targeting AML, broad claims |
| WO2019112345 |
Pfizer |
2019 |
Small molecule kinase inhibitors in leukemia |
Landscape characteristics
- Major applicants: Novartis, Pfizer, BeiGene dominate, frequently filing patents on kinase inhibitors for AML.
- Claim trends: Increasing focus on multi-kinase inhibitors, combination therapies, and targeting specific mutations like FLT3.
- Patent expiration: Core patents filed around 2014-2016, with expiry projected between 2034-2039, depending on jurisdiction.
Patent family distribution
Most patents focus on chemical compounds targeting FLT3 kinase, a significant driver in AML, with claims ranging from narrow (specific structures) to broad (compound classes).
Critical patent clusters
- FLK inhibitors: Focused on FLT3 kinase, including long-standing patents by Novartis.
- Multi-kinase inhibitors: Combining FLT3 and additional kinase targets.
- Use-specific innovations: Patent filings on treatment protocols and combinations with chemotherapeutic agents.
Analysis of patent claims and infringement risks
- The claims in CA2823218 are specific to its chemical structure class. Competing patents may pose infringement risks if their compounds fall within similar structural parameters.
- Since AML is a heavily patented area, freedom-to-operate analysis must include recent filings targeting FLT3 and other relevant kinases.
- Deviation from claimed structures or using different synthesis pathways may avoid infringement, but any overlapping compounds should be carefully analyzed.
Conclusion
Patent CA2823218 covers a specific chemical class of kinase inhibitors for AML, with claims extending to synthesis methods, formulations, and treatment methods. The patent landscape is highly active, dominated by key players focusing on FLT3 kinase and multi-kinase inhibitors. Its scope is solid within its molecular class but limited to AML, which guides strategic R&D choices.
Key Takeaways
- Patent CA2823218's claims are moderate in scope, primarily covering pyrimidine derivatives used to treat AML.
- The landscape is highly competitive, with multiple patents targeting similar kinase pathways.
- Narrower structural claims reduce infringement risk but require careful analysis of derivative compounds.
- Patent expiry windows extend into the early 2040s, providing a window for commercialization.
- Due diligence should include review of recent patent filings post-2019 for complementary or competing claims.
FAQs
1. Does CA2823218 cover other leukemia or cancers?
No, the patent specifically claims treatment of AML.
2. Are the synthesis methods in CA2823218 broadly protected?
They are specific but focus on certain chemical pathways; alternative methods may circumvent claims.
3. Can compounds outside the claimed structures infringe this patent?
Yes, if they fall within the scope of the chemical features claimed, especially similar core structures.
4. How does patent expiry affect commercialization?
Expirations around 2034-2039 open opportunities for generic development post-expiry.
5. What does the landscape suggest about future filings?
Expect continued filings on kinase inhibitors, especially multi-kinase targeting compounds, with evolving claims to cover broader chemical spaces.
References
- Canadian Intellectual Property Office (CIPO). (2019). Patent CA2823218, "Compositions and methods for treating leukemia."
- WIPO. (2019). Patent family data for WO2019112345, Pfizer’s kinase inhibitors.
- European Patent Office (EPO). Patent filings related to AML kinase inhibitors.
